Nu-Med Plus, Inc. filed its annual report on Form 10-K for the fiscal year ended December 31, 2025, disclosing its financial condition, business operations, and share information as of April 15, 2026.
Key Highlights
- Shares outstanding: The company reported 83,548,469 shares of common stock outstanding as of April 15, 2026.
- Market value of non-affiliate holdings: At June 30, 2025, the last sale price of the company's stock was $0.0740, resulting in an aggregate market value of common stock held by non-affiliates of $3,235,074.
- No exchange listing: The filing discloses no securities registered pursuant to Section 12(b) of the Act, with the common stock registered under Section 12(g) only.
- Company classification: The registrant identified itself as a non-accelerated filer, a smaller reporting company, and an emerging growth company.
- Not a shell company: The registrant indicated it is not a shell company as defined in Rule 12b-2 of the Exchange Act.
- Business focus: According to the filing, the company was incorporated in October 2011 to develop, manufacture, and market technologies utilizing nitric oxide in the medical device field.
Nu-Med Plus Annual Disclosure: Nitric Oxide Device Business and Financial Position
Nu-Med Plus, Inc., a Utah corporation incorporated in October 2011, filed its Form 10-K covering the fiscal year ended December 31, 2025. According to the filing, the company was formed "to develop, manufacture and market new technologies utilizing nitric oxide in the medical device field, primarily through the creation of a nitric oxide generating compound formulation and delivery systems." The company states it has developed a hospital nitric oxide delivery system, a clinical nitric oxide delivery system, a mobile rechargeable device to deliver nitric oxide gas, and a nitric oxide system for research applications. The filing identifies the company's headquarters as Salt Lake City, Utah, while also listing a principal executive office address of 640 Belle Terre Rd Building 2 E Port Jefferson NY 11777.
The company disclosed that as of June 30, 2025, the last sale price of its common stock was $0.0740 per share, producing an aggregate market value of common stock held by non-affiliates of $3,235,074. As of April 15, 2026, the company reported 83,548,469 shares of common stock outstanding. No securities are registered on a national exchange under Section 12(b); common stock is registered under Section 12(g) of the Exchange Act only, and no trading symbol is listed in the filing's registered-securities table.
The filing states that the registrant qualifies as an emerging growth company under the Jumpstart Startups Act of 2012, noting eligibility for certain exemptions from reporting requirements, including from the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002 and certain executive compensation disclosure obligations. The company also noted it qualifies as a smaller reporting company. The filing includes forward-looking statements and states that readers are "cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statement was made."
What Was Disclosed
Nu-Med Plus, Inc. submitted its fiscal year 2025 annual report disclosing its nitric oxide medical device business, share count of 83,548,469 as of April 15, 2026, a non-affiliate market capitalization of $3,235,074 based on a $0.0740 share price at June 30, 2025, and its status as a smaller reporting and emerging growth company with no national exchange listing.





Please wait processing your request...